Intervention not reported
Per cent mortality at 12 months (riluzole 100 mg) · patients with ALS/MND
The intervention leads to lower per cent mortality at 12 months (riluzole 100 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Functional impairment · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
2 findings from 1 review
Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
1 finding from 1 review
Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).
1 finding from 1 review
Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).
1 finding from 1 review
Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Adverse event: nausea · patients with ALS/MND
The intervention leads to higher adverse event: nausea (high certainty).
1 finding from 1 review
Intervention not reported
Adverse event: asthenia · patients with ALS/MND
The intervention leads to higher adverse event: asthenia (high certainty).
1 finding from 1 review
Intervention not reported
Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND
The intervention leads to higher adverse event: 3‐fold increase in alanine transferase (high certainty).
1 finding from 1 review